



bioMérieux launches 3P™ culture media range for cleanrooms and isolators

Lombard, IL – November 10, 2014 - bioMérieux Industry, a bioMérieux unit dedicated to industrial application diagnostics, announces the launch of 3P™, the new culture media product range specifically designed for cleanroom and isolator use. This advanced formulation was co-developed by a bioMérieux international research and development team and designed specifically for environmental monitoring in aseptic manufacturing environments.

“3P™ was tested for growth promotion from a library of 100+ organisms including USP strains and wild plant isolates. This product was developed with an innovative packaging system to manage moisture content in the product,” states Corinne de la Foata, Senior development scientist for bioMérieux.

bioMérieux’s Industry franchise delivers innovative products for industrial quality control laboratories, in particular for biopharmaceutical customers and provides solutions for environmental monitoring, microbial detection, sterility testing and microbial identification. 3P™ culture media for environmental monitoring enables flexible storage conditions from 2-25°C, a long shelf life of 24 weeks, and provides excellent neutralization capability for contact plates confirmed by testing against a wide array of disinfectants commonly used in pharmaceutical cleanrooms. The innovative packaging system manages product quality, enables a long shelf life and is resistant to vaporized hydrogen peroxide commonly used for isolator sterilization cycles.

“Development of 3P™ represents an important milestone for our biopharmaceutical customers and this new range delivers excellent performance over the product shelf life,” states Miguel Villa, VP Sales and Marketing for Industrial Applications, bioMérieux North America.

About bioMérieux

Pioneering Diagnostics

A world leader in the field of *in vitro* diagnostics for 50 years, bioMérieux is present in more than 150 countries through 41 subsidiaries and a large network of distributors. In 2013, revenues reached €1.588 billion with 87% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479). Other information can be found at www.biomerieux-industry.com/em

Contacts:

Media Relations

bioMérieux

Suzanne Jones

Tel: +1 919-479-3637

suzanne.jones@bioMérieux.com

Baker & Yorke

Tim Baker

Tel: + 1 216-338-8086

tbaker@baker-yorke.com

PRESS RELEASE